Jakarta, 31 May 2023 - PT Kimia Farma TBk (KAEF) has held a Annual General Meeting of Shareholders (AGMS) 2022 which was held offline and online (hybrid) which was attended by KAEF shareholders and held electronically with an e-proxy system that provided by the Indonesian Central Securities Depository.
The company has succeeded in reducing the company's cost of goods sold, so that it can decrease on an annual basis in the first quarter of 2023 to IDR 1.44 trillion. Thus, KAEF successfully recorded a gross profit growth of 14% to IDR 858.58 billion. KAEF recorded a total profit for the year that can be distributed to owners of the parent entity and non-controlling interests of IDR 24.63 billion in the first quarter of 2023. This realization increased compared to the same period in the previous year of IDR 2.58 billion.
Shortly after the 2022 AGMS, Kimia Farma held the 2023 Public Expose which was attended by media partners. In the agenda presented in 2023, KAEF continues to carry out business development strategies including accelerating product and service innovation, as well as business strengthening such as strengthening the end-to-end business portfolio and developing the vitamin, mineral and supplement (VMS) product category, strategic partnership with local and global institutions, as well as developing products in Anatomical Therapeutic Class 2 (ATC-2).
David Utama said that the company's positive achievements this year could not be separated from management policies in implementing operational excellence with path to profitability and the transformation of human resources. So it is not surprising that KAEF managed to record an improvement in its product sales portfolio with high margins, namely ethical and generic products. This made the Company managed to record a positive EBITDA of IDR 238.97 billion.